BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
6/8 — Strong
VYVGART (efgartigimod alfa) by argenx is neonatal fc receptor blockers [moa]. Approved for neonatal fc receptor blocker [epc]. First approved in 2021.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYVGART (efgartigimod alfa) is a neonatal Fc receptor (FcRn) blocker administered via injection that reduces circulating autoantibodies by blocking their recycling through FcRn. It is indicated for autoimmune conditions where pathogenic IgG antibodies drive disease, such as generalized myasthenia gravis. The mechanism works by preventing the salvage of IgG from cellular degradation, thereby reducing disease-driving antibody levels.
$200MPart D
PeakGrowing
VYVGART is in peak commercial phase with $200M in Part D spending, indicating a mature but still-expanding franchise supporting a growing commercial and medical affairs team.
Mechanism of Action
Neonatal Fc Receptor Blockers
Pharmacologic Class:
Neonatal Fc Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
Started Jul 2026
18 enrolled
Epidermolysis Bullosa (EB)Epidermolysis Bullosa AcquisitaRecessive Dystrophic Epidermolysis Bullosa+1 more
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
Started Jan 2026
25 enrolled
Myasthenia Gravis Generalized
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Started Nov 2024
680 enrolled
Myasthenia Gravis
Why This Matters for Your Career
Worked on VYVGART at argenx? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.